Helix BioPharma Corp.

TSX:HBP.TO

Biotechnology

Healthcare
$0.86 -4.70%

-$0.07 today

Market cap
$65.69M
Beta
-0.29
P/E (TTM)
-32.6
EPS (TTM)
-$0.04
52W Low $0.84High $5.40

Volume 0.00M

Average 0.00M

HBP.TO Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Helix BioPharma Corp.TSX: HBP.TO

Cost of Revenue · Q3 FY2026 · quarter ended Apr 2026

Cost of revenue declines year over year

Q3 FY2026 cost of revenue of CA$1K fell 66.7% year over year, behind the -37.5% change in trailing-twelve-month cost of revenue. Sequentially, it rose 0.0% from the prior quarter. Over 3 fiscal years it compounded at -5.9% a year.

Context

  • Cost of revenue increased in 2 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -66.7% toward the trailing-twelve-month pace of -37.5%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterApr 2026
CA$1K+0.0% QoQ
Last fiscal yearJul 2025
CA$10K-28.6% YoY
LTMApr 2026
CA$5K-37.5% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-66.7%——
1 year-28.6%——
3-year CAGR-5.9%——
5-year CAGR——
10-year CAGR——

Cost of Revenue history

CAD · from the income statement

Latest · FY2025
10K CAD
Year-over-year change
-28.6%
4-year CAGR
-51.0%

Cost of Revenue vs competitors

How HBP.TO compares with its peers on the latest reported figures

  • Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -37.5% is the 3rd highest of 4, against a peer median of -23.4%.
  • Over three fiscal years its annual growth of -5.9% compares with a peer median of -15.3%.
HBP.TO Competitors
Cost of Revenue for HBP.TO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
HLS.TOHLS Therapeutics Inc.LTM Mar 2026$21.35M USD+122.0%+86.8%38.3%
SVA.TOSernova Corp.LTM Apr 2026CA$256.13K CAD-40.2%-8.0%—
CRDL.TOCardiol Therapeutics Inc.LTM Mar 2026CA$103.71K CAD-23.4%-22.6%—
MSCL.TOSatellos Bioscience Inc.LTM Mar 2026$5.77K USD—-88.9%—
HBP.TOHelix BioPharma Corp.LTM Apr 2026CA$5K CAD-37.5%-5.9%—
Peer median (excluding HBP.TO) —-23.4%-15.3%38.3%

Competitors are the stored peer set for HBP.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

CAD
Metric
FY2021
Jul 2021
FY2022
Jul 2022
FY2023
Jul 2023
FY2024
Jul 2024
FY2025
Jul 2025
Revenue00000
Cost of Revenue173K12K13K14K10K
Gross Profit(173K)(12K)(13K)(14K)(10K)
Gross Margin—————
Research & Development5.88M4.54M5.28M6.1M3.58M
Selling, General & Admin3.25M595K299K3.26M1.84M
Operating Expenses9.13M6.04M6.33M9.36M5.42M
Depreciation & Amortization173K12K13K14K10K
EBITDA(9.46M)(6.03M)(6.31M)(9.38M)(5.21M)
EBITDA Margin—————
Operating Income(9.61M)(6.54M)(6.28M)(9.37M)(5.43M)
Operating Margin—————
Interest Income154K47K31K17K
Interest Expense15K18K14K7K10K
Other Income / Expenses(443K)(523K)36K(25K)192K
Income Before Tax(9.57M)(6.56M)(6.29M)(9.4M)(5.23M)
Pre-Tax Margin—————
Income Tax Expense(1.66M)(484K)14K(132K)(28K)
Net Income(7.91M)(6.08M)(6.29M)(9.26M)(5.21M)
Net Margin—————
EPS (Basic)(0.29)(0.20)(0.16)(0.21)(0.09)
EPS (Diluted)(0.29)(0.20)(0.16)(0.21)(0.09)
Weighted Avg Shares27.58M29.9M38.65M44.49M55.74M
Weighted Avg Shares (Diluted)27.58M29.9M38.65M44.49M55.74M

Helix BioPharma Corp.

TSX:HBP.TO

Intrinsic Alpha fair value

Locked

Current Price

$0.86

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.